Giovanni Abbadessa

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath et al. · The Lancet Oncology · 2012 · 550 citations

Medicine, Oncology, Pharmacology +9

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic et al. · The Lancet Oncology · 2018 · 349 citations

Medicine, Oncology, Pharmacology +11

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Sean D. Reiff, Rose Mantel, Lisa L. Smith et al. · Cancer Discovery · 2018 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

Yi Yu, Ronald E. Savage, Sudharshan Eathiraj et al. · PLoS ONE · 2015 · 121 citations · Full text

Medicine, Oncology, Pharmacology +14

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

Kyriakos P. Papadopoulos, Bassell F. El-Rayes, Anthony W. Tolcher et al. · British Journal of Cancer · 2017 · 95 citations · Full text

Medicine, Oncology, Pharmacology +14